Congress moves to cap drug prices at international levels, threatening pharma profits
S. 1587 — Fair Prescription Drug Prices for Americans Act · Filed by Josh Hawley (R-MO) · 1 cosponsor · Introduced May 5, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill caps U.S. prescription drug prices at the average price charged in Canada, France, Germany, Italy, Japan, and the United Kingdom. Manufacturers that charge more than this international reference price face civil penalties equal to 10 times the price difference per unit sold. The bill requires drug makers to report their U.S. and foreign prices annually to the Department of Health and Human Services.
Why we flagged it
The bill's core mechanism is a price cap tied to international benchmarks, enforced through civil penalties. This is straightforward price regulation, not a subsidy, carve-out, or hidden rider—the title accurately describes the function.
What the text implies
- Manufacturers may respond by raising prices in reference countries to avoid the penalty, shifting the cost burden internationally rather than reducing it globally.
- The bill does not address rebates, discounts, or negotiated prices—only 'retail list price'—which may create incentives for manufacturers to shift revenue to rebate structures that bypass the cap.
The full analysis lists 5 implications of this text.
Who stands to gain
patients and consumers (lower drug costs); health insurance companies (lower claims costs); pharmacy benefit managers (lower acquisition costs)